New approaches to atrial fibrillation management: Treat the patient, not the ECG

Cardiovascular Therapeutics

Volumn 28, Issue 5, 2010, Pages 302-310

  Pinter, Arnold ^a   Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Arrhythmias; Atrial fibrillation; Coagulation Thrombosis; Dagibatran; Dronedarone

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BENZOFURAN DERIVATIVE; CELIVARONE; CLOPIDOGREL; DABIGATRAN; DRONEDARONE; IDRAPARINUX; PLACEBO; RIVAROXABAN; UNCLASSIFIED DRUG; VERNAKALANT; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CATHETER ABLATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; ELECTROCARDIOGRAM; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEART DEATH; HOSPITALIZATION; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STROKE;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTROCARDIOGRAPHY; HUMANS; PREDICTIVE VALUE OF TESTS; STROKE; TREATMENT OUTCOME;

EID: 77956410762     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00135.x     Document Type: Review

References (51)

1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006 114 : e257 e354.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001 285 : 2370 2375.
3. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention. Circulation 2003 108 : 711 716.
4. Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. PACE 2009 32 : 981 986.
5. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the AFFIRM study. Circulation 2004 109 : 1509 1513.
6. Dorian P, Guerra PG, Kerr CR, et al. Validation of a new simple scale to measure symptoms in atrial fibrillation. Circ Arrhythmia Electrophysiol 2009 2 : 218 224.
7. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: A systematic review. Am J Med 2006 119 : 448. e1 e19.
8. Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M, Roy D. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002 143 : 984 990.
9. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomized trial. Lancet 2000 356 : 1789 1794.
10. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: An ACTIVE W substudy. J Am Coll Cardiol 2007 50 : 2156 2161.
11. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004 43 : 47 52.
12. Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias - Results of the SOPAT trial. Eur Heart J 2004 25 : 1395 1404.
13. Bertaglia E, Tondo C, De Simone A, et al. Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation: A 6-year multicentre experience. Europace 2010 12 : 181 187.
14. Kircchof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: Executive summary. Eur Heart J 2007 28 : 2803 2817.
15. Pontoppidan J, Nielsen JC, Poulsen SH, Hansen PS. Symptomatic and asymptomatic atrial fibrillation after pulmonary vein ablation and the impact on quality of life. PACE 2009 32 : 717 726.
16. Sintetos AL, Roark SF, Smith MS, McCarthy EA, Lee KL, Pritchett ELC. Incidence of symptomatic tachycardia in untreated patients with paroxysmal supraventricular tachycardia. Arch Intern Med 1986 146 : 2205 2209.
17. Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation 1991 83 : 119 125.
18. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 358 : 2667 2677.
19. Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation. Am J Cardiol 2004 93 : 1247 1253.
20. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: The A4 study. Circulation 2008 118 : 2498 2505.
21. Atwood JE, Myers JN, Tang XC, Reda DJ, Singh SN, Singh BN. Exercise capacity in atrial fibrillation: A substudy of the Sotalol-amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). Am Heart J 2007 153 : 566 572.
22. Lim KT, Davis MJ, Powell A, et al. Ablate and pace strategy for atrial fibrillation: Long-term outcome of AIRCRAFT trial. Europace 2007 9 : 498 505.
23. Wyse DG. Pharmacological and electrical cardioversion of atrial fibrillation to sinus rhythm: Is it worth it? Circulation 2009 120 : 1444 1452.
24. Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, Inoue H. Rate control and quality of life in patients with permanent atrial fibrillation. Circ J 2006 70 : 965 970.
25. Boriani G, Biffi M, Diemberger I, Martignani C, Branzi A. Rate control in atrial fibrillation: Choice of treatment and assessment of efficacy. Drugs 2003 63 : 1489 1509.
26. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833.
27. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 : 1834 1840.
28. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA 2001 285 : 2864 2870.
29. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest Sep 17, 2009 doi : Epub ahead of print
30. S, Pogue J, Hart R, et al. The ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomized controlled trial. Lancet 2006 367 : 1903 1912.
31. Connolly SJ, Pogue J, Hart R, et al. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009 360 : 2066 2078.
32. Healey J, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk. Stroke 2008 39 : 1482 1486.
33. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008 118 : 2029 2037.
34. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991 84 : 469 481.
35. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): Randomized controlled trial. Lancet 2003 362 : 789 797.
36. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 2005 293 : 690 698.
37. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomized, open-label, noninferiority trial. Lancet 2008 371 : 315 321.
38. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 361 : 1139 1151.
39. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007 357 : 987 999.
40. Hohnloser SH, Crijns HJ, Eickels M, et al. Effects of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009 360 : 668 678.
41. Connolly SJ, Crijns HJGM, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009 120 : 1174 1180.
42. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008 358 : 2678 2687.
43. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic S, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007 50 : 35 40.
44. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008 117 : 1518 1525.
45. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery. Circ Arrhythm Electrophysiol 2009 2 : 652 659.
46. Roy D, Pratt CM, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo controlled, multicenter trial Abstract). J Am Coll Cardiol 2006 47 : 10A.
47. Kowey PR, Aliot EM, Capucci A, et al. Placebo-controlled double-bind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter Abstract). Heart Rhythm 2007 4 : S72.
48. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. Heart Rhythm 2007 4 : 816 861.
49. Terasawa T, Balk EM, Chung M, et al. Systematic review: Comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med 2009 151 : 191 202.
50. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006 354 : 934 941.
51. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005 293 : 2634 2640.